Clomicalm 20 mg (30 tablets)

View other items in the same category as Clomicalm 20 mg (30 tablets)

Price $26.95

Product Uses

Clomicalm Tablets should be used as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age. Inappropriate barking, destructive behavior, inappropriate urination or defecation may be alleviated by the use of Clomicalm Tablets in conjunction with behavior modification. Clomicalm Tablets are not recommended for other behavior problems, such as aggression.

Product Contains

Clomipramine hydrochloride

Dosage and Administration

The recommended daily dose of Clomicalm tablets is 2 to 4 mg/kg/day (0.9-1.8 mg/lb/day), administered as a single daily dose or divided twice daily based on patient response and/or tolerance of the side effects. To reduce the incidence of vomiting that may be experienced by some dogs, Clomicalm may be given with a small amount of food. Once the desired effect is achieved and the appropriate behavioral modification has been successfully implemented, the dose of Clomicalm may be reduced to maintain the desired effect or discontinued altogether. Monitor the dog's behavior during the dose reduction or withdrawal period. Continued behavioral modification is recommended to prevent recurrence of the clinical signs.

Warnings, Side Effects and Drug Interactions

Clomicalm Tablets are contraindicated in dogs with known hypersensitivity to clomipramine or other tricyclic antidepressants. Clomicalm Tablets should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor (e.g. selegiline, amitraz). Clomicalm Tablets are contraindicated for use in dogs with a history of seizures or in conjunction with drugs which lower the seizure threshold.

There is no specific antidote for clomipramine. Overdose in humans causes effects on the central nervous (e.g., convulsions) and cardiovascular (e.g. rhythm disturbances and elevated heart rate) systems. People with known hypersensitivity to clomipramine should administer the product with caution.

Caution is advised in using clomipramine with phenobarbital, anticholinergic or sympathomimetic drugs or with other drugs with nervous effects. Prior to elective surgery with general anesthetics, clomipramine should be discontinued for as long as possible. Clomicalm should be used with caution in dogs with cardiovascular disease, increased pressure within the eye or a history of glaucoma, urinary retention or reduced gut motility. Because clomipramine is principally metabolized in the liver, caution is advised in using this medication in the presence of preexisting liver disease.

Safety studies to determine the effects of Clomicalm in pregnant or lactating female dogs have not been conducted. Clomicalm should not be used in breeding males.

Adverse reactions seen in post-approval adverse drug experience reporting include: lethargy/depression, anorexia, elevation in liver enzymes, vomiting and diarrhea. Liver and bile duct disease has occurred, especially in the presence of pre-existing conditions or with concurrent administration of drugs metabolized via the liver. Additionally, in an overdose situation, the following signs have been reported: ataxia, enlarged pupils, elevated heart rate and vocalization. In pre-release trials, aggression (growling) was seen in a small proportion of dogs treated with clomipramine.

The effectiveness and clinical safety of Clomicalm for periods greater than 12 weeks has not been evaluated.

Storage

Store in a dry place at controlled room temperature, between 59° and 86°F (15-30°C).

Manufacturer

Novartis Animal Health

Registration Status

NADA # 141-120, Approved by the FDA

Federal law restricts this drug to use by or on the order of a licensed veterinarian.